[1]周立莉,周冬霞,徐壽華,等.多療程DC-CIK免疫療法治療晚期肺癌的臨床療效[J].醫學信息,2019,(20):5-8.[doi:10.3969/j.issn.1006-1959.2019.20.002]
 ZHOU Li-li,ZHOU Dong-xia,XU Shou-hua,et al.Clinical Efficacy of Multiple Courses of DC-CIK Immunotherapy in the Treatment of Advanced Lung Cancer[J].Medical Information,2019,(20):5-8.[doi:10.3969/j.issn.1006-1959.2019.20.002]
點擊復制

多療程DC-CIK免疫療法治療晚期肺癌的臨床療效()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
5-8
欄目:
肺癌與肺損傷專題
出版日期:
2019-10-15

文章信息/Info

Title:
Clinical Efficacy of Multiple Courses of DC-CIK Immunotherapy in the Treatment of Advanced Lung Cancer
文章編號:
1006-1959(2019)20-0005-04
作者:
周立莉1周冬霞1徐壽華1吳金蕓2蔡茂懷1
(1.江蘇省鹽城市第二人民醫院腫瘤內科,江蘇 鹽城 224000;2.伯仕利生物科技發展<鹽城>有限公司,江蘇 鹽城 224000)
Author(s):
ZHOU Li-li1ZHOU Dong-xia1XU Shou-hua1WU Jin-yun2CAI Mao-huai1
(1.Department of Oncology,the Second People's Hospital of Yancheng,Yancheng 224000,Jiangsu,China;2.Bursley Biotechnology DevelopmentCo.Ltd.,Yancheng 224000,Jiangsu,China)
關鍵詞:
DC-CIK肺癌免疫療法多療程
Keywords:
DC-CIKLung cancerImmunotherapyMultiple courses
分類號:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.20.002
文獻標志碼:
A
摘要:
目的 觀察多療程DC-CIK治療晚期肺癌的臨床療效。方法 選取2014年12月~2018年12月我院收治的化療后肺癌患者86例,采用隨機數字表法分為對照組和實驗組,各43例。對照組行1個療程DC-CIK治療,實驗組行3個療程以上的DC-CIK治療。比較兩組治療后療效、淋巴細胞水平、細胞因子水平、腫瘤標志物表達以及不良反應發生情況。結果 實驗組疾病控制率(69.77%)高于對照組(41.86%)。治療后兩組CD4+、CD4+/CD8+、NK表達均較治療前升高,且實驗組高于對照組(P<0.05);治療后兩組CD8+表達均較治療前下降,且實驗組低于對照組(P<0.05);兩組治療前后IL-4、IL-6、IL-10無明顯變化(P>0.05);治療后兩組IL-2、TNF-α、IFN-γ均較治療前升高,且隨著治療次數增加,IL-2、TNF-α、IFN-γ逐漸升高(P<0.05);治療后兩組AFP、NSE、CYfra21-1均較治療前下降(P<0.05);兩組第一次治療后CEA升高(P<0.05);實驗組末次治療后,CEA下降(P<0.05);兩組均未出現不良反應。結論 多療程DC-CIK免疫療法治療晚期肺癌臨床療效確切,能有效清除腫瘤細胞,且安全無副作用。
Abstract:
Objective To observe the clinical efficacy of multi-course DC-CIK in the treatment of advanced lung cancer. Methods 86 patients with lung cancer after chemotherapy from December 2014 to December 2018 were enrolled. The patients were divided into the control group and the experimental group by random number table, 43 cases each. The control group received one course of DC-CIK treatment, and the experimental group received three courses of DC-CIK treatment. The therapeutic effects, lymphocyte levels, cytokine levels, tumor marker expression, and adverse reactions were compared between the two groups.Results The disease control rate (69.77%) in the experimental group was higher than that in the control group (41.86%). The expressions of CD4+,CD4+/CD8+ and NK in the two groups were higher than those before treatment, and the experimental group was higher than the control group (P<0.05).The expression of CD8+ in the two groups decreased after treatment, and the experimental group was lower than the control group (P<0.05). There was no significant change in IL-4, IL-6 and IL-10 before and after treatment (P>0.05). The latter two groups of IL-2, TNF-α, IFN-γ were higher than before treatment, and with the increase of treatment times, IL-2, TNF-α, IFN-γ increased gradually(P<0.05).After treatment, AFP, NSE and CYfra21-1 were lower than those before treatment(P<0.05); CEA increased after the first treatment in both groups (P<0.05); CEA decreased after the last treatment in the experimental group(P<0.05); no adverse reactions occurred in either group.Conclusion Multi-course DC-CIK immunotherapy is effective in the treatment of advanced lung cancer. It can effectively remove tumor cells and has no side effects.

參考文獻/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Heather Wakelee.50 Years of Progress in the Systemic Therapy of Non-Small Cell Lung Cancer[J].Am Soc Clin Oncol Educ Book,2014:177-89. [3]Hirsch FR,Scagliotti GV,Mulshine JL,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311. [4]吳軍,楊小平.分子靶向藥物治療非小細胞肺癌的研究進展[J].醫學理論與實踐,2019, 32(10):1489-1490. [5]Ren PT,Zhang Y.Comparative investigation of the effects of specific antigen?sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells[J].Mol Med Rep,2017,15(4):1533-1538. [6]人體細胞治療研究和制劑質量控制技術指導原則(國家食藥監督局文件), http://samr.cfda.gov.cn/WS01/CL0237/15709.html [7]Gao D,Li C,Xie X,et al.Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients[J].PLoS One,2014,9(4):e93886. [8]韋莊怡,任小朋,王博.DC-CIK自體回輸對化療后胃癌患者T淋巴細胞亞群及NK細胞的影響[J].臨床和實驗醫學雜志,2019,18(11):1179-1182. [9]單海霞,黃廣清.DC-CIK聯合化療治療進展期胃癌45例的臨床療效評價[J].胃腸病學和肝病學雜志,2014,23(12):1416-1419. [10]王金爍,謝澤新,李慧杰.DC-CIK聯合化療治療晚期胃癌的近期療效[J].實用腫瘤雜志,2016,31(1):38-42. [11]吳有軍,曹志宇,張慶軍.DC-CIK對結直腸癌根治術后肝轉移患者療效和循環腫瘤細胞的影響[J].中國腫瘤生物治療雜志,2018,25(1):89-93. [12]Mai HX,Mei GH,Zhao FL,et al.Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy[J].Cancer Res Ther,2018,14(Supplement):S427-S432. [13]Qin W,Xiong Y,Chen J,et al.DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells[J].Cell Mol Med,2018,22(7):3364-3376. [14]Hu J,Hu J,Liu X,et al.Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer[J]. Medicine,2017,96(42):e8310. [15]Xiao X,Ye X,Xu C,et al.Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen[J].Onco Targets Ther,2018,29(11):7555-7558. [16]Dhupkar P,Gordon N.Interleukin-2:Old and New Approaches to Enhance Immune-Therapeutic Efficacy[J].Adv Exp Med Biol,2017(995):33-51. [17]Gong W,Hoffmann JM,Stock S,et al.Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells[J].Cancer Immunol Immunother,2019,68(7):1195-1209. [18]Wang L,Wang Y,Song Z,et al.Interferon Cytokine Res[J]. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development,2015,35(4):273-280.

相似文獻/References:

[1]尤 靜.肺癌患者外周血CEA、NSE、CYFRA21-1聯合檢測的意義[J].醫學信息,2018,(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
 YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Medical Information,2018,(20):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹曉美,王莉娜.肺癌患者疾病不確定感的影響因素與干預措施研究現狀[J].醫學信息,2018,(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
 DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Medical Information,2018,(20):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]邢益輝,劉 曼,厲瑪倩倩,等.快速康復對肺癌手術患者并發癥發生及生活質量的影響研究[J].醫學信息,2018,(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
 XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Medical Information,2018,(20):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[4]朱曉曉,張 順,蔡 挺.鎳暴露相關的肺癌發生分子機制研究[J].醫學信息,2018,(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
 ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Medical Information,2018,(20):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[5]付云杰.肺癌患者血漿D-二聚體、NSE及CYFRA21-1聯合檢測的臨床價值[J].醫學信息,2018,(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
 FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Medical Information,2018,(20):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[6]覃柳麻,何慧敏.2014~2016年廣西腫瘤醫院肺癌患者流行病學及病理分布特征分析[J].醫學信息,2019,(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
 QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Medical Information,2019,(20):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[7]魏優蕾,郭曉彤.肺癌患者血漿檢測腫瘤標志物的分析方法及展望[J].醫學信息,2019,(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
 WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Medical Information,2019,(20):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[8]楊壽林,宋慶志,吳路發,等.腫瘤標志物和凝血指標在肺癌輔助診斷中的效果分析[J].醫學信息,2019,(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
 YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Medical Information,2019,(20):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
[9]郭 磊,王小文,向小勇.中性粒細胞與淋巴細胞比值與肺癌預后關系研究[J].醫學信息,2019,(09):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
 GUO Lei,WANG Xiao-wen,XIANG Xiao-yong.Relationship between Neutrophil-lymphocyte Ratio and Prognosis of Lung Cancer[J].Medical Information,2019,(20):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
[10]王 猛.循環腫瘤細胞在肺癌診療中的臨床研究進展[J].醫學信息,2019,(15):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]
 WANG Meng.Progress in Clinical Research of Circulating Tumor Cells in the Diagnosis and Treatment of Lung Cancer[J].Medical Information,2019,(20):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图